Multimodal assessment of protein functional deficiency supports pathogenicity of BRCA1 p.V1688del.
Unequivocal discrimination between neutral variants and deleterious mutations is crucial for appropriate counseling of individuals with a BRCA1 or BRCA2 sequence change. An increasing number of variants of uncertain significance (VUS) are being identified, the unclassified biological effect of which poses clinical concerns. A multifactorial likelihood-based approach recently suggested disease causality for BRCA1 p.V1688del, a VUS recurrent in Italian breast/ovarian cancer families. Whether and how this single amino acid deletion in the BRCA1 COOH terminus (BRCT) domain affects the function of the mutant protein (DeltaValBRCA1) has not been elucidated. We undertook comprehensive functional characterization of DeltaValBRCA1, comprising comparative structural modeling, analysis of protein stability and associations, and analysis of DNA repair function. Our model predicted BRCT domain destabilization and folding disruption caused by BRCA1 p.V1688del. Consistently, the recombinant DeltaValBRCA1 was less stable than wild-type BRCA1 and, unlike the latter, failed to associate with BRIP1, CtIP, and Rap80 and to relocalize to sites of DNA damage. Yeast two-hybrid analysis revealed a compromised interaction with FHL2 and KPNA2, which is likely responsible for improper subcellular localization of DeltaValBRCA1. In addition, we found four new breast/ovarian cancer families of Italian ancestry who carried this sequence alteration. These results provide the first evidence of the effect of BRCA1 p.V1688del on protein stability and function, supporting the view that it is a deleterious mutation. Multimodal analyses like ours could advance understanding of tumor suppression by BRCA1 and ultimately contribute to developing efficient strategies for screening and characterization of VUS.
De Nicolo
Arcangela
A
Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, USA. Arcangela_Denicolo@dfci.harvard.edu
Parisini
Emilio
E
Zhong
Quan
Q
Dalla Palma
Maurizia
M
Stoeckert
Kathryn A
KA
Domchek
Susan M
SM
Nathanson
Katherine L
KL
Caligo
Maria A
MA
Vidal
Marc
M
Cusick
Michael E
ME
Garber
Judy E
JE
D019943:Amino Acid Substitution; D019313:BRCA1 Protein / Q000737:chemistry / Q000235:genetics* / Q000378:metabolism; D024682:BRCA2 Protein / Q000737:chemistry / Q000235:genetics; D001943:Breast Neoplasms / Q000235:genetics* / Q000378:metabolism; D005260:Female; D020022:Genetic Predisposition to Disease; D018398:Homeodomain Proteins / Q000737:chemistry / Q000235:genetics / Q000378:metabolism; D006801:Humans; D060850:LIM-Homeodomain Proteins; D008958:Models, Molecular; D009124:Muscle Proteins / Q000737:chemistry / Q000235:genetics / Q000378:metabolism; D009154:Mutation; D011485:Protein Binding; D017510:Protein Folding; D055550:Protein Stability; D011994:Recombinant Proteins / Q000737:chemistry / Q000235:genetics / Q000378:metabolism; D014157:Transcription Factors / Q000737:chemistry / Q000235:genetics / Q000378:metabolism
D019313:BRCA1 Protein; D024682:BRCA2 Protein; C105987:FHL2 protein, human; D018398:Homeodomain Proteins; D060850:LIM-Homeodomain Proteins; D009124:Muscle Proteins; D011994:Recombinant Proteins; D014157:Transcription Factors
J Biol Chem. 2003 Dec 26;278(52):53007-16
14534301
Blood. 2006 Jun 1;107(11):4223-33
16493006
Oncogene. 2002 Dec 16;21(58):8981-93
12483514
Exp Cell Res. 2003 Jan 15;282(2):59-69
12531692
Clin Cancer Res. 2008 Jul 15;14(14):4672-80
18628483
J Mol Biol. 2005 Jan 14;345(2):275-87
15571721
Hum Mutat. 2007 May;28(5):477-85
17279547
Am J Hum Genet. 2004 Oct;75(4):535-44
15290653
Structure. 2004 Jul;12(7):1137-46
15242590
Methods. 2004 Apr;32(4):363-70
15003598
Biochemistry. 2005 Aug 23;44(33):10941-6
16101277
Nat Struct Mol Biol. 2004 Jun;11(6):512-8
15133502
J Biol Chem. 2001 May 4;276(18):14537-40
11278247
Hum Mutat. 2008 Nov;29(11):1314-26
18951449
Proc Natl Acad Sci U S A. 1999 Apr 27;96(9):4983-8
10220405
Science. 2003 Oct 24;302(5645):639-42
14576433
Nat Struct Biol. 2001 Oct;8(10):838-42
11573086
FEBS Lett. 2003 Oct 9;553(1-2):183-9
14550570
Cell. 1997 Aug 8;90(3):425-35
9267023
Hum Mutat. 2008 Nov;29(11):1265-72
18951437
Genomics. 2007 Mar;89(3):307-15
17207965
J Clin Oncol. 2008 Jan 1;26(1):16-7
18165634
Fam Cancer. 2006;5(1):77-88
16528611
Mutat Res. 2000 Aug 30;460(3-4):319-32
10946236
Exp Cell Res. 2004 Feb 1;293(1):14-21
14729053
J Mol Biol. 1993 Dec 5;234(3):779-815
8254673
Hum Mol Genet. 2001 Feb 15;10(4):353-60
11157798
Cell. 1997 Jan 24;88(2):265-75
9008167
Nat Struct Mol Biol. 2004 Jun;11(6):519-25
15133503
Hum Mutat. 2008 Nov;29(11):1261-4
18951436
Science. 1996 Apr 5;272(5258):123-6
8600523
Cancer Res. 2006 Feb 15;66(4):2019-27
16489001
Cancer Res. 2007 Feb 15;67(4):1494-501
17308087
J Clin Oncol. 2008 Jan 1;26(1):26-31
18165637
Annu Rev Genet. 1998;32:95-121
9928476
Cell. 2001 Apr 6;105(1):149-60
11301010
J Biol Chem. 1996 Dec 20;271(51):32863-8
8955125
Cancer Lett. 2008 Nov 28;271(2):179-90
18550271
Mol Cell. 2004 May 7;14(3):405-12
15125843
Curr Opin Genet Dev. 2002 Feb;12(1):86-91
11790560
Trends Mol Med. 2006 Nov;12(11):537-44
17011236
Annu Rev Pathol. 2009;4:461-87
18954285
J Biol Chem. 1998 Sep 25;273(39):25388-92
9738006
Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):13595-9
8942979
Nature. 1996 Aug 22;382(6593):678-9
8751436
Nucleic Acids Res. 2006 Mar 06;34(5):1416-26
16522651
Science. 2003 Oct 24;302(5645):636-9
14576432
Cancer Biol Ther. 2004 Jun;3(6):515-20
15254424
Genes Dev. 2006 Jan 1;20(1):34-46
16391231
Mol Cell Biol. 2004 Nov;24(21):9478-86
15485915